




The relative strengths and weaknesses of Akero Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akero Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Akero Therapeutics Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 131% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	355,173
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,083
Liabilities, Non-Current	1,079
Other Assets	1,350
Other Compr. Net Income	64
Other Expenses	739
Other Liabilities	9,846
Other Net Income	-115,156
Other Revenues	3,862
Property and Equipment	47
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	356,570
Liabilities	30,008
Expenses	739
Revenues	3,862
Stockholders Equity	326,562
Net Income	-112,033
Comprehensive Net Income	-112,001
BaseVar	253,200
ECR before LimitedLiability	310%
Economic Capital Ratio	376%